Pharmaceutical industry – Page 11
-
ResearchProtein impurities found in AstraZeneca’s Covid-19 vaccine stir debate
Compounds might cause side effects but are unlikely to be behind extremely rare blood-clotting events
-
BusinessMorphosys agrees to buy cancer epigenetics specialist Constellation
$1.7bn deal will be funded by selling rights to royalties on existing drugs
-
BusinessUS supreme court will not hear J&J talc appeal
Decision means J&J must pay $2.1 billion previously awarded to 22 women who say talc caused their ovarian cancer
-
WebinarThe age of digital chemistry
Join us to learn how data can solve existing bottlenecks in synthetic chemistry and why data analysis demands a multidisciplinary approach
-
BusinessStriving to bolster the antibiotic pipeline before it becomes the next crisis
It’s been almost 10 years since the world was warned of a post-antibiotic apocalypse. Katrina Megget takes a look at the initiatives trying to support antimicrobial R&D
-
BusinessUS supreme court ends Sandoz–Amgen biosimilar dispute
Sandoz’s copy of arthritis drug Enbrel won’t be available in the US until 2029, 30 years after it was first marketed
-
OpinionThe side effects of being unique
Even the largest clinical trials won’t capture all possible bad reactions to a drug – we need pharmacovigilance
-
WebinarA recipe for success in exploiting machine learning and data science
Join us to discover how data science and big data are revolutionising decision making – and why claims that experts are no longer needed are misleading
-
WebinarStatistics versus machine learning: should we all learn artificial intelligence?
Join us to understand the limitations of deep learning & why advanced statistical modelling is still needed – both in academic curricula and in the toolbox of any scientist or engineer
-
ArticleUnlocking the future of medicines manufacturing with digital innovations
The Medicines Manufacturing Innovation Centre promises to revolutionise how we formulate, trial and produce medicines
-
BusinessAntibody–drug conjugates drive growth in oncology
Antibody–drug conjugates are coming of age and pharma is investing, reports Katrina Megget
-
OpinionHow the pandemic might change drug research
Derek Lowe muses on some positive lessons learned
-
BusinessWhy manufacturing Covid vaccines at scale is hard
Exploring the pinch points vaccine makers face as they ramp up production
-
OpinionWhy are impurity regulations different for food and drugs?
The pharmaceutical and food industries should work together more closely on genotoxic impurities
-
FeatureFlow chemistry surges forward
The long-discussed technique could help make pharma manufacturing more distributed, finds Andy Extance, and create opportunities for chemists with the right skills
-
BusinessUniversity team’s silica coats stop vaccines spoiling at room temperature
Asel Sartbaeva hopes her pioneering ensilication technology will be adopted to store and transport pediatric vaccines to low-income countries
-
BusinessCoronavirus variants stymie success of monoclonal antibodies
Lab-made antibodies can treat and protect people from Covid-19 but are more likely to succeed when administered as a cocktail
-
OpinionA rough guide to pharma partnership deals
Coronavirus vaccines are driving unusual collaborations with a range of benefits
-
WebinarGaining an edge through smarter experimentation
Learn how to double your R&D capacity and get more products to market in less time – and at a lower cost
-
BusinessBiggest venture yet of any pharma company into cannabis
Jazz Pharmaceuticals buys cannabinoid therapeutic firm for $7.2 billion, inheriting first plant-derived cannabinoid medicine ever approved by FDA